The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
about
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
The tyrosine-kinase inhibitor ...... tastatic renal cell carcinoma.
@en
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial
@nl
type
label
The tyrosine-kinase inhibitor ...... tastatic renal cell carcinoma.
@en
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial
@nl
prefLabel
The tyrosine-kinase inhibitor ...... tastatic renal cell carcinoma.
@en
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial
@nl
P2093
P2860
P50
P1476
The tyrosine-kinase inhibitor ...... tastatic renal cell carcinoma.
@en
P2093
Abir Khalil-Mgharbel
Alban Deroux
Aude Salomon
Bernard Escudier
Céline Ferlay-Segura
Delphine Borchiellini
Ellen Blanc
Gilles Pages
Helena Polena
Jean-Louis Quesada
P2860
P2888
P304
P356
10.1038/S41416-018-0054-5
P407
P577
2018-03-22T00:00:00Z
P6179
1101634639